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This project explores mental health professionals’ perspectives on the 
prescription of psychotropic medications to children. It emphasizes the placement of 
biomedicine within its larger social, economic, and political context, and the influence 
these structures have on the way mental illness is conceptualized and treated in children. 
Eight semi-structured interviews were conducted in Denver, Colorado with 
psychiatrists, psychologists, social workers, and a pharmaceutical board member to 
capture multiple perspectives from different positionalities within the field. Participants 
discussed factors that they believe influence prescribing practices including: 
professional role changes, issues of access, limited evidence, cost, and institutional 
pressures to practice within a biomedical model of care. This thesis suggests that the 
supremacy of biomedicine has changed the conversation of mental health so drastically 
over the past forty years that psychological and social factors are no longer being 
legitimately considered as part of mental health care, to the detriment of children in 




The Way It Is 
 
There’s a thread you follow. It goes among 
things that change. But it doesn’t change. 
People wonder about what you are pursuing. 
You have to explain about the thread. 
But it is hard for others to see. 
While you hold it you can’t get lost. 
Tragedies happen; people get hurt 
or die; and you suffer and get old. 
Nothing you do can stop time’s unfolding. 
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 After graduating with a Bachelor of Science degree in psychology, I was 
employed in Flagstaff, Arizona as a Behavioral Health Specialist at a residential home 
for children. These children were either runaways, had been removed from their homes 
and were awaiting placement, or were part of the foster care system or the juvenile 
detention system. One of my duties there, depending on my shift, was to assist in the 
administration of medications before school and before the children went to bed. There 
was a giant white board, usually covered by a curtain in the office where staff could 
type notes and conduct shift updates. The white board included every child’s name, 
because every child was on a medication. It listed the generic name, the brand name, the 
dose, and additional information such as “must be taken with food,” or “make sure to 
cut in half before administering.” What the white board did not say was each 
medication’s intended effect. Was it to relieve anxiety? Was it help them focus? The 
medications were administered, crossed off a checklist, and re-administered in the 
evening. They were never discussed in staff meetings and we were never educated on 
their uses, side effects, or interactions. During one of my shifts, my co-worker who was 
studying to get into medical school brought his text book on pharmaceuticals, and we 
began looking up the medications from the whiteboard. What we discovered through 




a dosage level meant for a grown man, some were being given two medications meant 
to relieve the same symptom, and some had been taking a medication for several year 
when it was intended for short term use only. 
My initial reaction was anger. These children appeared to be being given drugs 
to make them focus in the morning, drugs to make them fall asleep, drugs to make them 
completely numb. They rarely had medication reviews while staying at our facility, and 
because these children were constantly on the move, they rarely had cohesive care 
teams following up on their prescriptions. This situation is perhaps unique, and in many 
ways extreme, but it drove me to explore the process of prescribing psychotropic 
medications to children in general.  
The process that results in children being prescribed these medications is 
important to understand and describe. Children often have little agency over their own 
health-related decisions, and instead decisions are usually made for them by parents and 
care providers. It is especially important therefore to understand this process to ensure 
that children with mental health issues are being cared for in informed, appropriate, 
efficacious, and ethical ways.  
Psychotropic medications are any pharmaceutical drug capable of affecting the 
mind, emotions, and behaviors (Merriam Webster 2018). Their use is a comment on 
health, on social expectations, on politics, on industry, and on ideology, yet the 
mechanisms of these drugs and their long-term effects on children are often unknown 
even by medical professionals and the pharmacological industry. Opening up the  
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conversation about how and why these medications are prescribed allows for a larger 
conversation surrounding mental health and its relationship to pharmaceuticals and 
biomedicine to be had in the future.  
For my thesis, I wanted to understand how mental health professionals, 
prescribers and non-prescribers, feel and think about these medications and their use 
with regard to patients under the age of eighteen. I interviewed psychiatrists, 
psychologists, a Colorado pharmaceutical board member, and social workers to collect 
a broad spectrum of experiences and explore their prescribing habits and relationships 
with these medications. The professionals I interviewed discussed the following factors 
as influencers of their prescribing practices: professional role changes, issues of access, 
limited evidence, cost, and institutional pressures to practice within a biomedical model 
of care. I discovered that many of my interviewees believed that these issues are the 
result of conceptualizing mental health as existing within a biomedical framework, 
which reduces the conversation of causality to biology and eliminates the possibility of 
psychological and social explanations as well as non-pharmaceutical treatments. 
For this project mental illness is operationally defined as any experience of 
unwanted or maladaptive emotions and/or behaviors including but not limited to 
depression, anxiety, attention deficit disorder, obsessive compulsive disorder, eating 
disorders, and aggression. In other discussions of health, ‘illness’ is used to describe the 
patient’s experience of symptoms, while ‘disease’ is the recasting of illness in terms of 
pathology (Kleinman 1988). The word illness is used in this thesis instead of the word  
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disease because several interviewees indicated that the pathology of mental health 
issues is often unknown and therefore it is the experiences of patients that informs the 
discussion of cause and treatment.  
It is also important to note that this thesis is not attempting to identify the 
pathology of mental illness or advocate for a specific treatment. It is an exploration of 
the consequences resulting from mental health moving rapidly along on the continuum 
from social constructionism towards scientific objectivism (Conrad and Bergey 2015). 
It focuses on how mental health has been treated since the 1980s with the introduction 
of the biomedical model in mental health, how this modal shift has impacted pediatric 
populations, and what may be being missed due to the shift and narrowing of care 






The first chapter of this thesis describes the adoption of the biomedical model of 
care by the mental health field beginning in the 1980s. It describes the roles of 
professionals within the field and addresses the use of and policies surrounding 
psychotropic medications for children both nationally and specifically in Colorado. The 
second chapter introduces the lens of critical medical anthropology which I apply 
throughout the project. This theoretical framework places biomedicine within its larger 
economic, political, and social context and allows it to be critically analyzed in the same 
way as any other cultural system. The third chapter outlines my methodological 
approach which utilized qualitative data collection and analysis techniques and allowed 
the data to inform my overarching themes presented in the following chapter. My 
results are presented in three separate sections within the fourth chapter: roles and 
relationships, resources and access, and the biomedical model. The fifth chapter 
presents my discussion of these three results categorizes. It explores the placement of all 
these factors within the context of the biomedical model and how this framework 
reduces conversations regarding psychological and social factors regarding mental 
health.  The paper concludes in the sixth chapter, which summarizes my findings and 
provides recommendations for further consideration of anthropologists and mental 





Chapter 1: Context 
 
Psychiatry in the United States  
 
By the end of the 19th, and throughout the 20th century, psychiatrists provided 
both therapeutic and medical treatments for their patients (Buchanan 2003). This 
combination of treatments reflected the blend of organic and psychological explanations 
given for mental illnesses at the time. While some illnesses such as “hysteria” were 
treated with the removal of women’s ovaries, others such as “neuroses” were treated 
with hypnosis and psychoanalytic therapy (Whitaker and Cosgrove 2015). It was 
understood that the body and the mind interact, and treatments reflected this symbiosis, 
though larger social factors were not largely considered at this time (Wilson 1993). 
This coupling of practice techniques remained the norm until the 1980s, which 
marked a drastic shift within psychiatry in the United States. Insurance companies 
became the predominant third-party payers, controlling coverage for patients and 
reimbursements for professionals, with the highest reimbursement coming from the 
prescription of psychotropic medications (Cummings 2015). National psychiatric 
institutions also began pushing psychiatry towards a biomedical model of care through 
the publication of the third Diagnostic Statistical Manual (DSM III) in 1980, which 




treatments (Kleinman 1988). These institutional changes and pressures from insurance 
companies, national psychiatric institutions, the DSM, and a collaboration with 
pharmaceutical companies led to a massive increase in the use of psychotropic 
medications for mental health issues. A comparison of the data from 1987 to almost a 
decade later shows an increase in the overall annual rate of psychotropic medication use 
in children from 1.4 per 100 persons in 1987 to 3.9 in 1996 (Olfson et al., 2002). The 
increase in the prescription of psychotropic medications for children reflects the 
changes occurring in psychiatry during the 1980s and 90s, and by the end of the 1990s 
psychiatrists were predominantly prescribing psychotropic medications over other 
therapeutic techniques (Kleinman 1988, Harris 2011).  
 
Professional Roles in Mental Health Care 
 
 At the same time that the role of psychiatrists were changing, other mental 
health professions began to gain popularity. While there are many sub-fields in mental 
health, the primary categories are psychiatrists, psychologists, and master’s level 
therapists, counselors, and social workers. Therapists, counselors, and social workers 
have a master’s degree and are usually trained in one specific form of therapy such as 
cognitive behavioral therapy, family therapy, or drug therapy but are unable to diagnose 
or prescribe medications. Psychologists have a doctorate degree and are trained in a 
wide variety of therapeutic techniques and can diagnose patients but not prescribe them 
medications. Psychiatrists have a medical degree with additional training in psychiatry 




To become a psychiatrist today, one must complete four years of undergraduate 
school, five years of medical school, and four years of residency. This is a conservative 
estimate, assuming a student is taking a full-time, continuous course load throughout 
their education. As of 2014, the median debt for this level of schooling ranged from 
$170,000 to $200,000 (Doctorly.org 2014). The financial and time commitments this 
professional route takes has led to a national shortage. As of 2009 there were only 10 
full time practicing psychiatrists in the U.S per 100,000 people, when it is estimated that 
25.9 are needed per 100,000, leaving the United States 45,000 psychiatrists short 
(Konrad et al. 2009). This shortage of professionals has led to long wait times for those 
seeking services. For child psychiatrists specifically, the wait time ranges from 28-81 
days for a first appointment (Steinman et al. 2015).  
Though historically psychiatrists were trained in both therapeutic and medical 
practices, an industry shift towards biomedicine and the public utilization of alternative 
mental health professionals led psychiatrists to reaffirm their now defining qualification 
within the mental health market: the ability to prescribe psychotropic medications. 
Psychiatrists thus moved closer to an affiliation with biomedicine and rebranded 
themselves as doctors who treat the brain with psychotropic medications (Kleinman 
1988).  
	
Psychotropic Medications and Children 
 
Psychotropic medications have been used for the treatment of emotional and 




Though the prevalence of these medications has continued to increase, “no current data 
shows even modest improvements in the incidence or prevalence or prognosis of any 
condition routinely treated today with psychotropic medications, including 
schizophrenia, bipolar disorder, and depression” (Cohen 2003, 6,). These medications 
are designed to manage symptoms, not to prevent, treat, or cure mental illness, because 
the pathology of mental illness is still unknown. Current theories however, such as the 
chemical imbalance theory, propose that the efficacy of these drugs is due to their 
ability to alter the number neurotransmitters in the brain. This implies that negative 
behaviors and emotions are experienced because of neurological malfunctions. Cohen 
writes that 
 
…laypersons and professionals come to believe and repeat that 
hopelessness and depression result from inadequate serotonin 
neurotransmission which is remedied by serotonin reuptake 
inhibitors…or that restlessness and inattention in millions of American 
school children result from frontal lobe shrinkage and that stimulants 
help the brain to grow…. The reality is of course more complex: people 
experiencing psychological distress take drugs because they want to, or 
because others want them to, or because alternatives to drugs are 
expensive, time-consuming, demanding, and less easily available. 
(Cohen 2003, 10) 
 
The use of psychotropic medications for the treatment of unwanted emotional and 
behavioral symptoms implies that the cause of these symptoms is predominantly 
biological. This organic explanation quickly gained popularity with the public, and the 
incidence of psychotropic prescription rates have steadily increased over the past 




1996 to 2007, every category of psychotropic medication has increased in prevalence 
amongst children with the exception of mood stabilizers, which dropped by 0.64% 
nationally. One of the most striking increases is the concurrent use of more than one 
psychotropic, which rose from 14.3% to 20.2% (Comer et al. 2010). A more recent 
study conducted in 2013 by The National Health and Nutrition Examination Survey 
collected data rates of adolescents aged 12-19 during a one month period. They found 
that 6.3% of adolescents reported using a psychotropic medication during that month, 
but that only half (53.3%) of those adolescents had seen a mental health professional in 
the past year. They also found that 4.5% of adolescents aged 12-19 had taken one or 
more psychotropic during the one month period (Jonas et al. 2013).  
This practice, the prescribing of more than one psychotropic medication at a 
time, is referred to as polypharmacy, and though almost no research has been done to 
examine the long-term effects of this practice, thousands of children are receiving this 
form of treatment in the United States every year (Comer et al. 2010). A 2014 study 
found that 39.4% of patients seen by 1000 child psychiatrists between 2007 and 2008 
were prescribed more than one psychotropic medication	 (Kearns and Hawley 2014). 
While polypharmacy is not inherently inappropriate, there is little evidence to support 
its efficacy, and the high rates of polypharmacy do not reflect the consensus of many 
researchers and physicians that the use psychotropic medications for children, 
especially in combination, should be a treatment course of last resort (Brenner 2014; 
Comer et al. 2010; Crimson 2007). In tandem with the increase in polypharmacy is an 




Off-labeling is the “prescription of medications without U.S FDA (Food and 
Drug Administration) approval for the condition or population to whom they are being 
prescribed” (Kearns and Hawley 2014, 438).  Much like polypharmacy, off-label 
prescribing is not inherently evidence of poor practice. Most psychotropic medications 
have not been approved for use in children by the FDA, which forces physicians to 
prescribe drugs to children without FDA approval (Brenner 2014; Comer et al. 2010; 
Kearns and Hawley 2014). However, off-labeling can pose a threat to the health of 
children when not used appropriately, and its prevalence amongst children is rising 
(Brenner 2014, Comer et al., 2007). In the study conducted by Kearns and Hawley 
(2014) described above, 55.1% of patients seen by 1000 child psychiatrists between 
2007 and 2008 were prescribed a medication off label (Kearns and Hawley 2014). 
There is little research to support off-label practices, and even less research showing the 
long-term effects for children (Brenner 2014; Comer et al. 2010; Crimson 2007). 
The inappropriate use of polypharmacy and off-label prescribing of 
psychotropic medications can have devastating effects on children over time. Though 
few studies have been done on the long-term side effects, those that have been done 
recorded inappropriate behaviors related to the practice from both prescribers and 
patients. These behaviors included the over-under-use of medications, contraindicated 
prescribing of medications together, medication errors, non-compliance, off-labeling, 
therapeutic duplication, prescribing decisions based on educated guesses rather than 
scientific evidence, and difficulty assessing new symptoms (side effects of medications 




outcomes for patients including adverse reactions to drugs, harmful drug-to-drug 
interactions, cumulative toxicity, compounded effects, and increased morbidity and 
mortality (Kukreja et al, 2013, 88). 
 
Psychotropic Medications and Children in Colorado 
 
The high rates of off-labeling and polypharmacy for psychotropic medications 
amongst children has received attention from state health departments and other 
concerned stakeholders. Colorado issued its own report in 2013, publishing data 
collected between 2008 and 2011 on the 414,880 children and adolescents enrolled in 
Colorado’s State Medicaid program, which represents 40% of children in Colorado 
(KFF Henry J. Kaiser Family Foundation 2017). It found that 20,040 (4.8%) of these 
children were taking a psychotropic medication and that 2,615 (13%) were taking more 
than one (Colorado Department of Health Care Policy and Financing and Colorado 
Department of Human Services 2013). The same study compared findings from 
Colorado with those found in Maine, Missouri, New Hampshire, New York, Oklahoma, 
Pennsylvania, and Tennessee. Averaging the data found in all eight states (including 
Colorado) showed that 6.9% of children on Medicaid were taking an antipsychotic, 
while 25% were taking another mental health drug (Colorado Department of Health 
Care Policy and Financing and Colorado Department of Human Services 2013). This 
was compared to rates within Colorado where 5.6% of Medicaid children were taking 
an antipsychotic, and 17.4% were taking a mental health drug. Though both statistics 




off-labeling and polypharmacy are relatively high. Of the 5.6% of Colorado children on 
Medicaid taking an antipsychotic, 3.4% were at or above the maximum dosage level 
(off-labeling), and 21.6% were prescribed multiple antipsychotics simultaneously 
(polypharmacy) (Colorado Department of Health Care Policy and Financing and 
Colorado Department of Human Services 2013). These data show that though 
Colorado’s prescription rates are comparatively low, they are not immune to the high 
rates of off-labeling and polypharmacy seen across the country.  
 
Prescribing Guidelines in Colorado 
 
The 2013 report outlines Colorado’s guidelines for prescribing psychotropic 
medications to children: 1) prior authorization is needed for any atypical antipsychotic 
for children under the age of five, which must be manually reviewed by a clinical health 
professional at the Department of Health Care Policy and Financing 2) Physicians are 
limited to the use of FDA approved indications only 3) physicians are encouraged to use 
the algorithm created by Colorado policymakers to help make prescribing decisions for 
children and psychotropic medications (Colorado Department of Health Care Policy and 
Financing and Colorado Department of Human Services 2013). These guidelines are not 
mandatory however, which leaves room for interpretation and noncompliance, which 
was observed during a follow-up report in 2016. This second review was conducted by 
the original reviewing department (Colorado Department of Health Care Policy and 
Financing) and partnered with Public Consulting Group (PCG) to evaluate the level of 




in the previous report. The major finding of this review was that adherence to, and 
comprehension of, the guidelines were low across all levels of the healthcare field 
(Colorado Department of Health Care Policy and Financing 2016). 
The guidelines suggest using the federal definition of ‘medical necessity’ when 
evaluating whether a child qualifies for the prescription of a psychotropic medication. 
The report found that behavioral health organizations were not considering this 
guideline when prescribing and were instead using their own definitions. Many were 
unaware that the guideline existed at all (Colorado Department of Health Care Policy 
and Financing 2016). Interviewees (physicians and non-physicians) also stated that 
there were too many changes and policies in Colorado for staff to successfully 
implement, and that these top-down demands for bureaucratic procedures were not 
effective at the ground level. Interviewees reported feeling confused regarding priorities 
in healthcare practices, and that they were constantly “trying to explain how 
[policy]changes fit into an overall strategy” (Colorado Department of Health Care 
Policy and Financing 2016, 20). The report concluded that the demands to integrate 
these policies created barriers for staff who are working directly with children and 
families, which was further compounded by a lack of adequate providers with 
experience in treating children and families in Colorado. In summation, the report states 
that one of the biggest weaknesses regarding Colorado’s health provisions for children 
through Medicaid is that “behavioral health systems [are] not responsive to the needs of 
children and adolescents…” (Colorado Department of Health Care Policy and 








I am using theories of Medical Anthropology to frame and analyze my research. 
Medical Anthropology examines human health and disease, systems of care, and 
contemporary adaptations to biomedicine (McElroy 1996). It acknowledges that health 
and health systems exist within larger contexts and are influenced and experienced 
through relationships and interactions with people, medications, and institutions (Lock 
and Scheper-Hughes 1996). A limitation of classical medical anthropology is the 
assertion that empirical research can lead to the discovery of pre-existing truths 
regarding the objects, or people, under study. It posits health and healing as something 
that can be known and explained through science and technological mastery, and that 
such pursuits will bring all healthcare closer to the biomedical model (Lock and 
Scheper-Hughes 1996). Critical Medical Anthropology (CMA) takes a more reflexive 







Critical Medical Anthropology (CMA) 
	
CMA acknowledges that the dominant ideas in health and healthcare are situated 
in their own social, historical, and political contexts. This requires the application of a 
critical gaze upon these modes of knowledge production, in order to increase what is 
 “seeable, knowable, and speakable among physicians” (Singer and Baer 1995, 59). 
Singer and Baer (1995) propose four levels from which to analyze healthcare and these 
structures of knowledge: 1) the individual level which includes patients’ personal 
networks and experiences with illness, 2) the micro-social level, which involves 
physicians’ relationships with other care providers and with their patients, 3) the 
intermediate social level which analyzes health policies and decision making, and 4) 
and the macro-social level which examines the political and economic context in which 
health and healthcare exists (Singer and Baer 1995, 63).  
These levels of analysis are only constructive however if a critical gaze is 
maintained to acknowledge and examine the supremacy of biomedicine in health and 
health care. Thus far, anthropologists have not examined the predominance of 
biomedicine with enough scrutiny because of its reputation as being “scientific,” and 
therefore “privileged and exempt from such analysis” (Lock and Scheper-Hughes 1996, 
43). This lack of cultural analysis has led to the assumption that biomedicine is 
objective, universal, and treats a “historical subject” which the critical-interpretive 
perspective challenges (Lock and Scheper-Hughes 1996, 43). While CMA allows us to 
better understand the context within which biomedicine exists, a critical-interpretive 




Understanding the experiences of the professionals I interviewed as they exist within 
this larger political and economic context allows their practices, as well as biomedicine, 
to be simultaneously explored and analyzed as structures made up of a “negotiation of 
meanings” and influence (Lock and Scheper-Hughes 1996).  
 
Conceptual Frame Work 
 
The Anthropology of Expertise  
	
Expertise is a way to simultaneously examine institutions, professions, and 
knowledge production. Within healthcare systems, none of these factors can be 
examined in isolation as each inform and contextualize the other. The anthropology of 
expertise explores how knowledge is acquired through institutions, how professional 
boundaries are distinguished through this acquired knowledge and through the 
relationships this knowledge allows people to have with socially valued objects (Carr 
2010). With the shift towards biomedicine, psychiatrists were able to reclaim their 
foothold in the mental health market due to their isolated knowledge on, and ability to 
prescribe psychotropic medications (Brodwin 2013). With an increasing deficit of child 
psychiatrists and an increasing need for pediatric services, this expert knowledge is 
beginning to be distributed between professionals, blurring these carefully constructed 
boundaries. The anthropology of expertise shows the reciprocal relationships that exist 
between the professionals I interviewed, knowledge production and consumption in the 
mental health field, other professional roles, and the reification of biomedicine and 




Barriers to Care 
 
Drs. Levesque, Harris, and Russell (2013) created a conceptual model to address 
issues of access within health care. Their model has five components: Approachability; 
Acceptability; Availability and accommodation; Affordability; Appropriateness 
(Levesque, Harris, and Russell 2013). Each component is a way of addressing and 
organizing barriers to healthcare including and extending past physical access. While 
several models of access exist, this model pays attention to the unique experiences of 
supply side (caregivers) and demand side (patient) factors (Levesque, Harris, and 
Russell 2013). This model is helpful when looking at the practical concerns of 
providing mental health care to children that were identified by the professionals I 
interviewed such as cost, resources, evidence, and professional availability.  
 
Biomedicine in Context  
 
The medical system within the United States is inextricably tied to its political 
and economic context. The structure and organization of these powerful institutions 
(state bureaucracies, welfare programs, insurance companies, research institutions, etc.) 
directly impact health policies and the way illness is conceptualized and treated 
(Petryna, Lakoff, and Kleinman 2006). Exploring biomedicine within its context reveals 
the interconnectedness of these factors and how they impact decision making regarding 
the creation, promotion, and utilization of pharmaceuticals. Biomedicine is often 




richer and more critical investigation of its influence in the field of mental health.  
Considering biomedicine within context and as context for the experiences of the 
























My research objective was to understand mental health professionals’ 
experiences regarding the prescription of psychotropic medications to children and the 
larger context within which those experiences exist. I wanted to better understand what 
factors influenced prescribing practices for the professionals I spoke with as well as 
how these factors relate to one another within the context of biomedicine. I was 
interested in data that explained prescribing practices as resulting from factors other 
than a discrete medical diagnosis, including practical factors such as cost and access as 
well as ideological factors such as models of care and institutional pressures (a full list 




This project is rooted in an empiricist epistemological approach (Bernard 2011). 
Within this approach I used inductive reasoning which is an essential component of 
Critical Medical Anthropology’s (CMA) analytic framework. A pillar of CMA is the 




biomedicine in healthcare (Singer and Baer 1995). I used a qualitative approach in both 
data collection and analysis as I am representing the experiences of mental health 
professionals in context in as broad and inclusive a manner as possible.  
My interviews consisted of one adult psychiatrist, two child and adolescent 
psychiatrists, two child psychologists, two licensed clinical social workers, and one 
member of Colorado’s Pharmacy and Quality Health Improvement Unit. I interviewed 
two professionals from each of the major categories (psychiatrists, psychologists, and 
master’s level professionals) in order to examine similarities and differences in their 
experiences both within and between professions. The adult psychiatrist was selected to 
provide an “outsider” yet still professionally informed opinion, and the pharmaceutical 
board member was interviewed to gather information regarding Colorado’s policies for 
these medications. 
 
Population and Sample 
 
The population of this study is all mental health professionals in Colorado. Each 
state has different guidelines regarding the prescription of psychotropic medications for 
children and it was therefore important to stay within one state while collecting data. 
Mental health professionals working with children, especially psychiatrists, are a 
difficult population to access due to their limited availability and limited numbers. 
These access constraints are even more pronounced in less populated cities, so I chose 
to isolate my sample to the highly populated city of Denver. My sample was selected 
using the chain referral method, utilizing online research and connections provided by 




Because I am interested in understanding the process of prescribing 
psychotropic medications to children, I collected cultural data from experts who can 
comment on cultural norms as well as variations from those norms (Bernard 2011, 113). 
This necessitated the use of nonprobability sampling, as I needed to capture the 
experiences of specific representatives within my population in order to gain an in-




My interviews began in May of 2017 and ended in August of 2017. All eight 
semi-structured interviews were conducted in the workplaces of each informant at their 
convenience. My guiding question for each interview was: What is your experience 
with children and psychotropic medications? From this initial point, I allowed 
participants to guide the conversation and probed when certain topics seemed 
particularly relevant to my investigation. These topics included medications, off-
labeling, polypharmacy, the role of insurance companies, disagreements between 
professionals, professional roles, anecdotes about particular cases, research, evidence, 
cost, professional/prescribing pressures, cultural shifts within psychology/psychiatry, 
national organizations, and policies.  
Each participant received a copy of an Institutional Review Board (IRB) 




recorded. The interview without audio recording (interview #2) allowed me to take 
notes and gave me permission to use direct quotes. All interviews were then transcribed 




I used qualitative techniques to process and thematically analyze my data 
through the iterative process of reading interview transcripts and finding themes that 
communicated patterns found throughout the interviews. By reading and rereading the 
interview transcripts, concepts that stood out as significant to my topic were 
highlighted, and later grouped into larger patterns due to similarity of content. The 
concepts identified as significant were chosen because of the level of frequency in 
which they appeared across interviews as well as their consistency with the findings in 
the literature presented in the background of this thesis.  This technique allowed me to 
discover three overarching patterns in the data: relationships/identity, resources, and 
political/economic structures. The results of this this thesis are organized according to 




I received approval for my study from the IRB at the University of Denver on 




participants received no compensation. The personal information of informants, with 
the exception of their professional title, was excluded from this thesis and the identity of 




Chapter 4: Results  
	
There is disagreement within the mental health field over the roles of different 
professionals (Kleinman 1988). These historic and contemporary disagreements find 
their roots in fundamental ideological differences over what mental health/illness is, 
how it is caused, and how it can be treated (Whitaker and Cosgrove 2015). These 
disagreements are complicated by concerns over financial, social, political, industrial, 
and personal pressures that both explicitly and implicitly influence the field and the 
practices within it.  
The three categories of mental health professionals utilized for this research are 
psychiatrists, psychologists, and professionals with a master’s degree in social work. 
Primary care physicians and pediatricians are also discussed throughout these 
interviews as they are becoming more involved in the prescribing of psychotropic 
medications to children. The scope and focus of each of these professional categories 
has changed dramatically over the past three decades, and these changes have been met 
with confusion and occasionally animosity from others within the field. Every 
interviewee I spoke with mentioned these role concerns, but depending on their 
professional positionality, their opinions ranged widely and helped affirm the 
proposition that these role changes are factors that have influenced the prescribing 




Roles and Relationships 
 
A child psychologist I spoke to discussed when he first began to see professional 
roles changing in mental health:  
 
What I do think is true is that since…the 1980s people with master’s 
degrees and doctoral degrees in psychology have been practicing what 
psychiatrists used to do. So psychiatrists have had to figure out, what is 
it that WE do? And what we do as psychiatrists is prescribe medication. 
So the whole field has become more medical. And less psychological 
because psychiatrists…keep getting backed into a drug…into a medicine 
corner. (Interview #3-child psychologist) 
 
The 1980s were a time of substantial change in the mental health field. The 
Diagnostic Statistical Manual (DSM)-III was published which redirected diagnoses and 
treatment away from psychoanalytic thought and towards a biomedical model of 
practice (Kleinman 1988). Before the 1980s, psychiatrists provided therapeutic services 
as well as medications, but the desire to make the field more “medical” led to 
professional role changes (Buchanan 2003). The child psychologist quoted above 
identified this institutional shift and how this process simultaneously led psychiatrists to 
affiliate more with their prescribing practices as psychologists and therapists began 




While the above quote was provided by a psychologist giving his opinion on 
how institutional shifts have influenced the practice of psychiatrists, a child psychiatrist 
I spoke to shared his thoughts on how the practices of all mental health professionals 
have been influenced by a “payer environment”: 
 
This payer environment sort of pushes prescriptions. So...there has been 
this sort of alphabet soup in mental health, where all these different 
people are taking different aspects of mental health…the payer 
environment has pushed providers towards practicing in very narrow 
ways. So as a psychiatrist you have an MD, maybe you have a couple 
hundred thousand dollars in debt, and the only way you’re going to get 
paid is to see kids on 15 or 30-minute intervals, and the only way you 
can reimburse at a higher rate is to throw a prescription in there. That’s 
a lot of pressure…And if you’re a psychologist you can’t get paid for 
prescribing! And it’s not worth your time to do therapy because there 
are bunch of therapists out there who need the clients to fill their hours, 
so you get pushed to doing just assessments, so that’s sort of what’s 
happening to psychologists. (Interview 6- child psychiatrist) 
 
This psychiatrist identified a financial factor that he believes is narrowing professional 
scopes of practice. As insurance companies began paying for mental health services as 
third party payers, the need arose for those services to be coded and billed. According to 




becoming specialized in a single aspect of mental health care in order to monopolize 
and optimize the billable market for that service: master’s level professionals are being 
reimbursed for therapy, psychologists for assessments, and psychiatrists for 
prescriptions.  
 The same child psychiatrist quoted above elaborates, saying that the division of 
professional roles has caused complications in how patients access care. The public may 
not be aware of the differences between professionals and their limited scopes of 
practice:  
 
So [professionals] are going to be in their own world view of how mental 
health should be treated. And you’re going to be…locked into that world 
view. And patients don’t know. It’s sort of alphabet soup…I am telling 
you because who you see will determine whether or not you get drugs. 
And you don’t only not get drugs, but you are locked into whatever their 
model of mental illness is. (Interview 6- child psychiatrist) 
 
The above comment was made while discussing how patients get connected with 
services. The child psychiatrist was telling me that one’s professional role is usually 
indicative of their view of mental health and how it should be treated. Therefore, who a 
patient sees will dictate how their mental health status is communicated to them (what it 
is, how it was caused, and how to treat/care for it). It will also determine whether or not 





a patient gets connected with for care is often random (as he says, it’s “alphabet soup”). 
The interviewee goes on to give an example of what this might look like in the medical 
field: 
 
Child Psychiatrist: So, if you went to the emergency room with chest 
pain, you would probably feel very uncertain and insecure if your care 
were then just by happenstance given to somebody with very different 
training than a physician. So you might get a cardiologist, or you might 
get somebody who went for two years to get a master’s degree in heart 
physiology, or you might get some sort of tech, or a Chinese 
acupuncturist…If you have a mental health complaint in today’s society 
you might get a therapist as your first point of contact and that therapist 
might be a social worker, they might be a child and family therapist, they 
might be a drug and alcohol counselor. You might get a psychologist 
who has very different training from a therapist. You might get a 
neuropsychologist. Or you might get a psychiatrist. 
Me: and you find that inconsistency problematic?  
Child psychiatrist: absolutely 
 
This child psychiatrist sees the inconsistencies surrounding who provides care, and 
therefore what care is provided, as problematic. In the analogy he provides of the ER 




room cardiac patient. This analogy was intended to show that some mental health 
professionals are inappropriate care providers for certain mental health patients. Though 
his explicit intent was to illustrate what he sees as problematic inconsistencies of care, 
there is also a comment being made about his world view. The comparison of a 
mentally ill patient with a cardiac patient reveals his close affiliation as a psychiatrist 
with biological models of health which differs greatly from that of others within the 
field.  
Different types of caregivers have begun practicing so narrowly and have such 
defined and often opposing ideas about mental health pathology that a patient’s care and 
treatment will be completely different depending on who they see (Buchanan 2003). 
According to the psychiatrist above, the narrowing of scopes within professional roles 
limits patients’ ability to experience a variety of care options and instead “locks” them 
in to whatever “world view” their caregiver (assigned at random) happens to have.  An 
adult psychiatrist I spoke with endorsed that she, too, has seen the role of psychiatrists 
continue to shift towards medicine and away from other forms of therapeutic services: 
 
The adult psychiatrist I spoke with discussed a shift she has seen in the 
medical community, beginning a decade ago and continuing today. She 
categorized physicians (including psychiatrists) educated during this 
time as “classically trained” and explained that these classically trained 
physicians were not being trained to endorse alternative treatments to 




style considerations (nutrition, exercise, substance use, etc.) and that she 
does not think these physicians are taking that information into 
consideration before prescribing a medication. She attributes this 
change to a focus on “evidence-based medicine.” In her experience, 
both psychiatrist and primary care physicians are not collecting 
adequate patient information/histories before prescribing psychotropic 
medications. (Field note from (Interview #2 fieldnote-adult psychiatrist) 
 
The adult psychiatrist I spoke to above describes how the education system for 
physicians and psychiatrists has come to reflect the same narrow focus seen in practice 
across the field. She views the current education of psychiatrists as being focused on 
evidence-based medicine to the detriment of other life-style related factors regarding 
health. According to my interviewees, psychiatrists are not only being backed into a 
“medicine corner” due to institutional pressures and professional role changes, but 
through their education as well. A child psychologist went as far as to describe 
psychiatrists’ relationships with these medical treatments as addictive: 
 
I was just telling some students yesterday, Xanax is addictive…but who 
becomes addicted to it is the doctor not the patient. The doctor gives the 
Xanax, and it doesn’t work so they give more of it, and then they give 






This child psychologist was discussing with me one of the biggest issues he sees in 
child psychiatry: psychiatrists who become “addicted” to prescribing medical 
treatments. In the example he gives, he admonishes the protocol of prescribing a 
medication to a child, and if ineffective, simply increasing the dosage instead of 
considering other, non-medical, treatment options.  
In another interview, a different child psychologist told me that “everyone loves 
a depressed kid” (Interview #4 – child psychologist). She was implying that everyone 
prefers a child who is void of difficult symptoms; a kid who is quiet, withdrawn, and 
lethargic is much easier to deal with than a child with positive symptomology such as 
aggression, hyperactivity, or self-harm. The process of raising the dosage of a drug like 
Xanax, mentioned above, eliminates unwanted symptoms by bringing patients closer 
and closer to catatonia, as common side effects include: fatigue, amnesia, slurred 
speech, disturbed coordination, and can be highly addictive (Ballenger et al. 1988; 
Klerman 1988; Tone 2009).  This drug’s efficacy lies in its ability to mask symptoms by 
sedating patients (Ballenger et al. 1988). 
Psychiatrists’ affiliation with these medications seems to be moving them farther 
away from understanding pathology and closer to basic symptom management 
(Kleinman 1988). This observation was affirmed by the child psychologist, quoted 
above, who provided this brief case study: 
 
Child psychologist: So fast forward to what I do now…I am seeing a 5-year-old 




reason I am seeing him is because he’s anxiety driven, very busy you know, and 
he is being cared for by his maternal grandmother while his mother serves time 
for neglecting him. She goes to her GP and he puts him on imipramine.  
Me: do you remember what dose? 
Child psychologist: All I remember...God’s honest truth, is grandma saying, ‘if 
one is good, two are better’ and she brought in a stoned catatonic 5 year old. 
Everybody loves a depressed kid…And the worst thing is, we’re not dealing with 
underlying pathology. We are treating symptoms. So this little boy who has 
anxiety disorder, needed a very involved caregiver, which his grandmother was 
too tired to provide… 
 
This example introduces the perception held by this, and other psychologists that I 
interviewed, that these drugs are being prescribed to address symptom management at 
the neglect of addressing pathology. This psychologist believed that a more involved 
caregiver would have helped address the underlying causes of this child’s anxiety, but 
he was instead prescribed a medication indicated for nerve pain and depression to treat 
his symptoms. The same child psychologist later said that: 
 
In my opinion Ellie, it’s just gotten to be a bad business, where shrinks 
sit in the office like you and I are and I say ok now you go home and you 
give your kid these five pills. I should see you a few times. We don’t 




Is if in rebuttal to this accusation of “armchair” psychiatry, a child psychiatrist told me 
that this negative perception has nothing to do with concerned psychologists, and has 
more to do with money: 
 
Psychologists want prescribing privileges because that’s another way to 
get money. And of course they will say that it’s just a way for them to 
give holistic treatment. But remember, psychologists have zero medical 
training. Psychologists haven’t taken a single class in physiology, never 
did a neuro exam. (Interview 6- child psychiatrist) 
 
The role of psychiatrists in the mental health field has changed over the past several 
decades. According to my interviewees, these changes seem to have created 
professional divides, especially between psychologists and psychiatrists. One of the 
psychologists perceives psychiatrists as “addicted” to medical treatments, unconcerned 
with pathology, and blind to psychological and social factors affecting mental health. 
While one of the psychiatrists perceives psychologists and other professionals as 
improperly trained to handle patients with mental illness, and as money hungry 
opportunists, trying to wiggle their way into psychiatrists’ elite space of prescribing 
privileges. In contrast, this professional animosity did not appear in my interviews 








While the above quotes show professional and ideological divides between several 
professionals I interviewed, participants also discussed instances of professional 
collaboration. According to a licensed clinical social worker (LCSW) I spoke to, 
master’s level professionals will often consult with a psychiatrist to update them on the 
progress a patient who has been prescribed a medication: 
 
I always try to collaborate with the prescriber, so it feels like a joint 
team. So once referred I will update the prescriber on what I’m seeing 
emotionally, behaviorally… are they less anxious, and what are the 
benefits? Or, I’m not seeing anything and do we need to think about a 
different med or upping the dose, kind of having those conversations 
about what’s working and what’s not working (Interview #5 - LCSW) 
 
This LCSW is describing a scenario where the psychiatrist is responsible for prescribing 
a medication and she, as the LCSW, is responsible for monitoring and reporting on the 
progress of the child. It is interesting to note here that if the medication prescribed is not 
working, the LCSW and psychiatrist discuss “a different med or upping the dose” and 
not non-pharmacological interventions.  
The collaborative relationship described above is consistent with the ideal model 





I mean the ideal setting is a doctor that has a working relationship with 
the other people trying to help the kid. So that they don’t have to see the 
kid that often because they have people they are collaborating with. To 
give them feedback and report (Interview #3 - child psychologist) 
 
This model describes a psychiatrist with limited time, and a care team designed to 
support the psychiatrist by giving feedback and reports on the progress of their mutual 
patient. These two quotes however are the only two that discuss collaborative efforts 
between mental health professionals throughout my interviews. The rest of the 
conversations revolved around collaboration between psychiatrists and primary care 
physicians and pediatricians.  
Due to the deficit of child psychiatrists in the United States, and a mounting 
need for pediatric services, primary care physicians and pediatricians are now becoming 
a prominent part of this biomedical mental health care team (Smith 2012). The 
pharmaceutical board member I spoke to explained that an effort had been made within 
Colorado to help primary care physicians prescribe these psychotropic medications to 
children: 
 
For a while in Colorado we had this thing called C-PACK [Colorado 
Psychiatric Access and Consultation for Kids], and it was funded by the 
health foundation, and they had a bit more of an intensive intervention 




intensive educational program over time for pediatricians and family 
docs. And one of the things they found was that for the most part, people 
taking the class thought they couldn’t stop these medications. And some 
of them didn’t feel like they knew how to do that or have that 
conversation. (Interview #7 Pharmaceutical Board Member) 
 
This educational program revealed that though primary care physicians and 
pediatricians in Colorado were often prescribing or monitoring pediatric patients taking 
psychotropic medication, they often did not feel equipped to do so. This knowledge has 
led to an emphasis on creating connective services that allow primary care physicians 
and pediatricians to consult with psychiatrists when prescribing these medications. A 
child psychiatrist told me: 
 
I am starting to do some telehealth work in the emergency room. I 
actually interface quite often, at least on a daily basis, with my 
colleagues in other specialties in medicine…constantly interfacing with 
the pediatric emergency medicine doctors and then we also field calls 
from the community to pediatricians…so pediatrics in the community, 
outpatient pediatricians, children’s hospital, they can call for 
consultation, really around anything you know…[pediatricians] could 
call and ask about medication, if they had a question about how to dose 




the system and how to get kids and families connected to treatment, we 
could help link them with resources. I think that the overarching goal of 
a child psychiatrists is to practice at the top of my license meaning that I 
will provide consultation to primary care providers around fairly simple 
and straight forward cases, so if they have questions around how to dose 
a stimulant, or what the specific side effects for anti-depressants that we 
need to look out for, and then I can give them consultation you know 
kind of continue to follow along with them as long as they feel 
comfortable prescribing the medication (Interview - 1 child psychiatrist) 
 
 
Telehealth, an increasingly popular advancement in health care, allows physicians to 
consult with one another and with patients over the phone or video chat without having 
to meet in person. In this example, telehealth is a tool pediatricians and primary care 
physicians can use to consult with psychiatrists when prescribing psychotropic 
medications to children. Through this process, psychiatrists are beginning to share their 
expert knowledge with other professionals. According to my interviews, this type of 
collaboration is occurring between psychiatrists and other physicians but does not 
appear to be as common between psychiatrists and other mental health professionals.  
 
Resources and Access 
 
It has become clear through these interviews that prescribing psychotropic 




care physicians. It is important to understand what factors affect access to these 
prescribers, and what resources are or are not utilized within a biomedical model of 
mental health care. Access factors include physical and geographical barriers to 
physicians, affordability on both the supply (physician) and demand (patient) side, and 
the adequacy of the care provided. The physical barriers that limit access to physicians 




The limited number of child psychiatrists nationally, and in the state of 
Colorado, has made accessing prescribers a difficult task (MHA 2015). As previously 
discussed, a decreasing workforce, long wait times, and high costs make psychiatrists 
some of the most difficult mental health professionals to access, and a child psychiatrist 
I spoke to addressed what this limited access means for mental health within the 
community: 
 
I just think that there is trouble with access, not only with child 
psychiatrists, but with other mental health services as well. I think it’s 
hard to access providers just because there aren’t enough of us to sort of 
meet the need.…Child psychiatry has a very significant workforce 
issue…it’s an underserved population, children and adolescents with 




This interviewee mentions that access to many mental health services are limited, but 
the focus seems to be specifically on child psychiatrists’ inability to meet the needs of 
underserved pediatric patients.  Other than the above quote, no other interviewee 
mentioned any mental health services other than psychiatry as being difficult to access. 
The conversations more commonly revolved around issues of access to prescribers. The 
same child psychiatrist explains the repercussions of this disconnect between 
psychiatric supply and patient demand: 
 
 And because of the delay, as you might imagine, it can take up to two 
years to get these kids in to be seen. They’re growing, they are getting 
bigger, and aggression is a very common symptom for kids that don’t 
have the ability to speak or to communicate verbally. They act out 
behaviorally and these are often times the kids that end up with off-label 
prescribing, on high doses of medication, and multiple medications, 
because they are so unsafe, that their aggression is leading to property 
destruction, leading to assault on peers, teachers, family, self-injury, and 
that is really a significant problem, so it’s really in the interest of safety 
that these kids are on these medications and I think providers are doing 






According to this psychiatrist, a lack of physical access to prescribers is a barrier for 
many children in need of mental health care. And though collaboration with 
pediatricians and primary care physicians presumably alleviates some of these 
prescription related access constraints, it is still seen as a significant issue. According to 
this psychiatrist, while children and their families wait for care, symptoms often 
worsen, especially as children develop physically. She describes a prescribing pressure 
caused by long wait times that result in medications becoming the only available 
resource to ensure that child and others’ safety. There was no discussion of what 
services are or could be used supplementary until a child accesses a prescriber. In fact, 
though many of the interviewees identified access as a significant issue for children 
with mental health needs, they often did not discuss the issue beyond initially 
identifying it as problematic. As one child psychiatrist said plainly: 
 
…. the problem is freaking access! (Interview #6 – child psychiatrist) 
 
According to several of my interviewees, physically accessing prescribers is a difficult 
task for children and families. And a national workforce shortage of psychiatrists 
coupled with a growing need of services for young patients is leading to long wait times 
(Steinman et al. 2015). According to the child psychiatrist I spoke to, during these wait 
times children often go without any care at all, leading to a worsening of symptoms and 
often making medications the only viable option for rapid symptom relief. This 




psychotropic medications, limits the recognition and utilization of non-biomedical 
resources for providing legitimate treatment and care for children.  
Cost 
Another factor influencing prescribing practices and access to care is cost. 
Within the mental health care system, there are two questions regarding cost: what are 
patients covered for and how much are professionals being reimbursed? Insurance 
companies are able to define their own criteria for “medical necessity” and therefore 
can decide which services are covered for which clients: medications, psychotherapy, 
emergency room visits, or inpatient facilities (APA 2018). A child psychiatrist 
discussed with me her experiences with these issues of cost, coverage, and affordability: 
 
And the other sort of challenge we run up against is you know what 
insurance companies and payers are willing to pay for, and so often 
times I think not because you’re wanting to…but because you’re wanting 
to help the child and family, is that sort of doing the best with what you 
have, meaning you can’t access a therapist, you can’t access in home 
therapy, you can’t access family therapy, the child doesn’t really meet 
the DSM criteria for depression but certainly has a lot of irritability and 
acting out behaviors, and so you sort of do the best with what you have, 
and sometime all you have is the possibility of a medication, maybe 
making an impact, in that particular situation to sort of help the child 




Even if this psychiatrist felt that therapy would be a more appropriate route of 
treatment, because insurance companies cover medications more than therapeutic 
services she is forced to practice within those financial constraints. If the choice for an 
insurance-covered treatment is medication or nothing, this interviewee recognizes that 
medication may be the only possibility for improving a child’s symptoms. Of note here 
is that in this case, the prescription of a medication is not the direct result of a diagnosis, 
but instead a result of institutional pressures and a desire to alleviate symptoms. After 
explaining this to me, the same child psychiatrist provided me with an anecdote to 
illustrate her point: 
 
We were seeing over 3,000 kids a year [in the emergency room], 
psychiatric patients, and these are kids in crisis and they come because 
they don’t have anywhere else to go and they are truly in crisis. So then 
having to fight with insurance companies about not only getting 
medications authorized, but even getting treatment authorized. Just as an 
example, I had a young patient who was in the foster care system and he 
was brought to the emergency room in crisis. He was found with a 
weapon and wanted to use it to kill his foster parents and kill himself, 
and he was having psychotic symptoms telling him to do these things, 
and the insurance company didn’t want to pay for hospitalization…It is 
much cheaper to pay for a couple of prescriptions for a child than it is to 




This psychiatrist believes that because the initial cost of hospitalization is much 
higher than that of a prescription medication, insurance companies are pushing these 
prescriptions in the face of overwhelming evidence that another course of treatment 
would be more appropriate. In this example, it appears that care is being dictated by 
what services are covered and not by what services are most appropriate.  
A child psychologist I spoke with discussed the constraints of cost and coverage 
more broadly, inferring that many pediatric mental health issues would be lessened if 
institutions invested in pre-emptive care instead of retroactively paying for illnesses that 
may have been prevented: 
	
Me: so that’s what’s lacking? Preemptive care? 
Child psychologist: Yes. That’s it.  That is absolutely it 
Me: and why don’t we do that? 
Child psychologist: because it’s expensive. People always say…and 
that’s the only thing I’ve ever heard, prevention is so expensive. But it’s 
so much easier to build health than rebuild pathology. (Interview #4 - 
child psychologist) 
 
Preventing mental illness in the first place is better for patients than treating a mental 
illness that has already manifested. But, according to this child psychologist, that is 
expensive. And according to the child psychiatrist above, insurance companies are 




of what is in the best interest of the patient. Insurance companies that cover prescription 
medications over other forms of mental health care are incentivizing patients to become 
life-long customers, taking medications for chronic conditions that never permanently 
alleviate symptoms (Whitaker and Cosgrove 2015).  
This pressure from insurance companies to pursue prescription treatments over 
all others also affects the prescribing practices of physicians as it directly influences 
their paychecks (Cummings 2015). This financial pressure was brought up during an 
interview with a child psychiatrist: 
 
Me: so you think that there is a potential that some of the discrepancies 
between how people are practicing is because of how they are being 
reimbursed by insurance companies? 
Child psychiatrist: yes. There is a lot of economic pressures pushing 
people into particular practice styles. (Interview #6 - child psychiatrist) 
 
The same child psychiatrist as above deconstructs how this pressure effects daily 
practice: 
 
So as a psychiatrist you have an MD, maybe you have a couple hundred 
thousand dollars in debt, and the only way you’re going to get paid is to 




reimburse at a higher rate is to throw a prescription in there. That’s a 
lot of pressure. (Interview # 6 – child psychiatrist) 
 
According to this psychiatrist, psychiatrists have a financial incentive to prescribe 
psychotropic medications. And the more children they see in a day, and the more 
medications they prescribe, the higher their financial reward. This is not to say that all 
psychiatrists practice with this mentality, but it is important to acknowledge financial 
pressure as a significant component in the relationship between cost and practice. Issues 




From these interviews, another major factor that was identified as hindering 
adequacy of care is the lack of research and evidence available regarding children and 
the use of psychotropic medications. These medications are part of the biomedical 
model which implies that their use must be supported by evidence-based medicine 
(Guyatt et al. 2002). Without evidence, prescribing practices cannot reflect this 
biomedical mandate. Several interviewees discussed a lack of overall research regarding 
children and these medications, a lack of knowledge regarding their long-term effects, 
pharmaceutical companies’ influences on study results, and a lack of approved pediatric 
medications by the FDA. A child psychiatrist explained to me that these issues are not 
the result of one major influencer, but rather a combination of multiple factors that 




There’s not like this evil psychiatrist out there listening to 
pharmaceutical companies (gives an evil laugh “mwahaha”) no, there is 
this profoundly disruptive kid that’s come to them, that’s fairly impaired, 
doesn’t know what to do, there’s no evidence out there (Interview #6 – 
child psychiatrist)  
 
This child psychiatrist is addressing the difficulties of prescribing a psychotropic 
medication when there is little evidence to support that practice for children. Ethical and 
safety concerns limit the number of studies conducted on children, which means that 
few psychotropic medications are approved for pediatric use by the FDA (AACAP 
2012). A LCSW I spoke to said that the limited number of FDA approved drugs reflects 
a lack of understanding of their efficacy among children: 
 
As you know there are still just a couple of meds that are FDA approved 
for kids, which says we are still trying to learn a whole lot more about 
what really helps (Interview #4 -  child psychologist) 
 
This comment implies that a measure of conservatism is being applied to the approval 
of these drugs because not enough is known about ‘what really helps’. While this is 
often the case, many psychotropic medications are discovered accidentally and are 
prescribed without a fundamental understanding of their efficacy (Whitaker and 




treatment even if the pathology of the illness and the medication itself remains 
unknown. A child psychiatrist explains that: 
 
We don’t know how [these medications] they work. We don’t know how 
lithium works. We don’t really know how the SSRIs work, we don’t really 
know how stimulants work. I mean we know a lot about the molecular 
pathways, the synaptic pathways, the parts of the brain that seem to 
recover with their use. But we don’t know why the depression goes away. 
And clinically it’s not that the depression goes away. Clinically people 
are less stressed and less reactive to SSRIs and then that helps ease 
anxiety and depression. But we are in the dark ages, remember? We 
don’t even know the fundamental mechanisms of the disorders… If you 
don’t know the physiology, then how the heck are you supposed to know 
how they work? (interview #6 – child psychiatrist) 
 
Lithium, Selective Serotonin Reuptake Inhibitors (SSRIs), and stimulants are used for 
symptom reduction in bipolar disorder, depression/anxiety, and attention deficit 
disorder, respectively. Yet what exactly makes these drugs effective remains unknown, 
as do the mechanisms of the disorders themselves (Kleinman 1988).	The ambiguity of 
these medications means that they are often prescribed off-label to treat disorders other 
than what the FDA has indicated them for (Brenner 2014). The lack of approved 




practices. These off-label practices are not formally endorsed by most states but are 
common across pediatrics, according to my interviewees.  
The pharmaceutical board member I spoke to said that instead of pushing for 
more research into illness pathology to understand what medications might be more 
effective and why, the issue of off-labeling has simply increased pressure on the FDA to 
approve more drugs. The pharmaceutical board member said: 
 
Lately the FDA has had a lot of pressure to increase approval of drugs 
and so sometime studies are…based on limited data or based on sort of 
shorter term things. (Interview #7 – pharmaceutical board member) 
 
From her perspective, the pressure for more psychotropic medications to be approved 
for pediatric patients has led to studies with questionable data being used to justify FDA 
approval. These studies create confusion in the field and make it difficult for prescribers 
to parse out accurate findings to best inform their prescribing practices. As a child 
psychiatrist told me: 
 
For every one set of information or one study you find one that says the 
complete opposite. (Interview #1 – child psychiatrist) 
 
Though this is  hyperbole, it captures the exasperation felt by many of my interviewees. 




are often controversial (Whitaker and Cosgrove 2015). A child psychologist I spoke 
with stated that while Xanax is indicated by the FDA as a treatment for panic disorders: 
 
Xanax backfires on panic attacks within weeks. But people still prescribe 
it. Because some research says it helps with panic attacks. SSRIS seem to 
have no effect whatsoever except that it sometimes makes kids suicidal 
and yet they are still prescribed for kid (Interview #3 child psychologist) 
 
The previous three quotes address concerns over how data is collected, interpreted, and 
presented. Physicians rely on the FDA and other organizations to read pharmaceutical 
studies and to create prescribing guidelines that accurately reflect the findings. Instead 
of reading the studies in full however, an interviewee I spoke to stated that many in the 
field rely on summaries written by the pharmaceutical companies themselves. The 
pharmaceutical board member I spoke with told me that: 
 
Board Member: Our DUR (Drug Utilization Review Committee), meets 
and they are almost half pharmacists, half doctors and one industry rep 
which is sort of interesting 
Me: Industry meaning pharmaceutical industry? 
Board Member: yes and they are responsible for making 




summaries and we can either accept, we usually accept, the 
recommendations of the DUR board 
Me: and where do these reviews come from? 
Board Member: we take whatever we can get. 
 
Even those responsible for making prescription guidelines for the state of Colorado do 
not have adequate access to the full gamut of evidence needed to make fully informed 
decisions regarding the approval of these medications. They often read summaries, 
written by companies with the greatest financial investment in a drugs success, to 
inform their decisions. 
Several interviewees described the lack of research as the primary barrier 
preventing them from prescribing psychotropic medications to children in a way that 
reflected evidence-based medicine.  But a child psychologist I spoke with argued that in 
addition to this problem, the information that does exist is not being critically examined:  
 
Well the weird thing is…that when you read the pharmaceutical study 
companies write up…everything is there that you need to know…[but] 
nobody in my field ever reads studies anymore. Everyone reads someone 
else’s review. And those summaries of drug studies are written by people 
that work for the drug companies… So, like a good example is using 
Ritalin for ADHD…What the original research found was that for kids, 




starting really at week one and going through 14 months. Then, it starts 
to even up, and over the course of three years kids without Ritalin are 
doing as well or better, and then after six years, kids without Ritalin are 
doing a lot better than the kids with Ritalin, including being an inch 
taller…. The issue at hand is that when the study was published, it was 
published as a study that went on for 14 months that showed amazing 
results. And then it’s only if you go to the actual material that they have 
to hand into the FDA that you find, oh! They also followed them for 6 
years but never wrote that up…To me the major issue is the reviews are 
written by people with a stake in the review (Interview #3 – child 
psychologist) 
 
There is clearly a lack of research and evidence to accurately inform the prescribing 
practices of psychotropic medications to children (Whitaker and Cosgrove 2015). And 
according to my interviewees, for the research that does exist, even those in charge of 
creating policies and prescription guidelines are only reading study summaries written 
by the pharmaceutical companies themselves. The psychologist quoted above believes 
that though the long-term data for studies is sometimes available, it is not sought after 
by prescribers and therefore is not used to inform their prescribing practices.  
This issue of long-term effects is of great concern, as these drugs are being 
given to children who are still developing physically and neurologically. A child 




I really do think there has to be a very compelling reason to recommend 
a medication to a child because we do not have as much information or 
research as we need to fully understand what these medications are 
doing to developing bodies and brains and that’s part of what I tell 
families all the time, that there really has to be a compelling reason to 
expose your child to this medication and, that’s really what our evidence 
based, best practice standard is (Interview #1 – child psychiatrist) 
 
A LCSW showed a similar sentiment after I asked her if she had seen children in her 
practice who had been prescribed off-label psychotropic medications. She said she had, 
and that this practice was done: 
 
With no comprehension that developing brains are vastly different than 
brains that have been properly developed (Interview #4 – child 
psychologist) 
  
If the evidence and research being conducted on children and the use of psychotropic 
medications is as limited and controversial as is being reported here, then the 
prescribing practices of psychiatrists and non-psychiatric prescribers are not being 
adequately informed. Though their affiliation with the biomedical model of care 




impossibility. There are aspects of mental health/illness and its affiliated treatments that 
do not fit within the biomedical framework into which they are being forced. 
 
 
Mental Health within the Biomedical Model 
	
The professionals interviewed for this project identified institutions such as 
insurance companies, professional organizations, and pharmaceutical companies all as 
influencing prescribing practices. These institutional pressures appear to be experienced 
and negotiated within the context of other influential factors such as access to care, 
research on psychotropic medications, and the roles and relationships of professionals 
within the field. From speaking with professionals, it appears that some of these 
influential power structures are difficult to identify or at least articulate. Several 
interviewees described the “system” in which they operated as being “damaged” or 
“broken”, but rarely connected this sentiment to the factors outlined in the previous 
results sections. A child psychiatrist I spoke with identified questionable prescribing 
practices as a symptom of this confusion and brokenness: 
 
 I think providers are doing the best they know to do in a difficult 
situation…what at times appears to be over or reckless prescribing or off 
labeling or what might seem inappropriate I think at times it certainly is, 
but at times it’s just a symptom of people doing the best they can within a 




She describes questionable prescribing practices as a symptom of psychiatrists having 
to negotiate care within a broken system. Yet she does not explicitly identify what is 
constraining treatment choices or connect this comment with ones she had previously 
made regarding research and cost. A LCSW I spoke with provided some more insight, 
claiming that the biomedical model is to blame: 
 
So this is my concern, is that the way the system, the [bio]medical model 
is, when you get 15 minutes with their prescriber, that they get the same 
monitoring, follow up, time to adequately assess what’s going on. It’s 15 
minutes. So in an ideal world, whether it’s a PCP, PNP or a psychiatrist, 
that we get more time to see what’s going on, what’s going on with the 
family, you know?	(Interview #5-LCSW) 
 
A child psychiatrist previously discussed how financial concerns have led psychiatrists 
to spend less time with their patients. This LCSW also blames the biomedical model for 
these rapid psychiatric assessments and diagnoses and is expressing concern over the 
quality of care that can be accomplished in 15 minutes. The “system”, identified here as 
the biomedical model, is influencing the quality and quantity of interactions between 
caregivers and their patients.  
In addition to efficiency, another key element of the biomedical model is 
organic explanations for health and illness (Wilson 1993). Within mental health, several 




that of chemical imbalances (Whitaker and Cosgrove 2015). A child psychologist I 
spoke to referenced this theory as well as a larger ideological shift he sees regarding the 
United States and its emphasis on the brain: 
 
A lot of medications just don’t help but people think they do… it’s this 
whole myth of chemicals. Chemical imbalance. I mean this idea that 
depression is a chemical imbalance. The whole country is fascinated 
with the brain. It’s like the brain is everything and psychology and 
anthropology are nothing… so we have a medical view of the human 
condition right now which leads to intervention. (Interview #3-child 
psychologist) 
 
This psychologist is commenting on a fundamental disagreement that still exists within 
the field of mental health; even after the herculean effort to move the field towards a 
biomedical model, we still do not agree on the causes of mental illness. This 
psychologist places proponents of the biomedical model on one side, viewing mental 
illness as derivative of biological or neurological disturbances, and psychologists and 
anthropologists on the other side, presumably considering psychological and social 
explanations for mental illness.  
Theories such as the chemical imbalance theory eliminate the need to discuss 
psychological and social factors. If the cause of mental illness is neurological, then the 




not the only treatments that affect neurology. Non-pharmaceutical psychotherapeutic 
treatments are also effective ways to change the brain (Kleinman 1988):  
 
The most target way to change the brain is to change 
experience…learning. That’s the most targeted. The brain is built to do 
that….	 the only thing that’s a targeted intervention right now that we 
know of for the brain is learning. So that’s definitely not meds but it’s 
definitely biologically based (Interview #7 – child psychiatrist) 
 
This quote shows the supremacy of biomedicine within the mental health field, 
and how much it influences prescribing factors. Even though treatments that focus on 
experience and learning accomplish the same result of altering neurology, without any 
of the potential side effects associated with psychotropic medications, psychiatrists are 
still prescribing medications over therapeutic treatments (Kleinman 1988).The same 
child psychiatrist proposes that broader societal pressures are also to blame for high 
prescription rates among children:  
 
 …a lot of kids are definitely medicated to behave within the social 
context that they’re expected to operate in, so their symptoms are 
causing some kind of functional imperative. But that’s a broader societal 





The implication of this comment is that instead of advocating to alter the environment 
of a child, prescribers are using medications to alter the child to better fit their 
environment. Though this psychiatrist has identified social factors that should be 
addressed when treating children with mental illness, they are not incorporated into his 
conception of the type of care he can provide. Whether he believes that “broader 
societal issues” should be dealt with by mental health professionals or not is unclear. 
What is clear, is that he has identified situations where children have been medicated in 
response to a social issue, and not a biological one. The biomedical model seems to be 
reducing the scope of what care providers think they should and can do for their 
pediatric patients. It is obstructing more holistic conversations that would address the 
interactions of broader societal and psychological issues in addition to biology.  
 A discussion I had during my final interview with a LCSW synthesized the 
previous themes of cost, resources, access, evidence, and biomedicine. This LCSW uses 
a technique called neurofeedback to treat her pediatric patients with ADD/ADHD. 
During this technique, patients can observe the frequency of their brain waves through 
either an audible or physical stimulation produced by the neurofeedback machine. They 
are encouraged to speak about issues surrounding their hyperactivity, anxiety, etc. and 
as they observe their brain waves increasing in response to their distress, they are 
encouraged to slow their brain waves down through breathing techniques and 
relaxation. When describing the technique to me, she explained that it has measurably 




companies nor considered a primary option for families due to the extended time for 
treatment: 
 
LCSW: you know, I would say, all the kids that can get access should be 
doing neurofeedback in my opinion 
Me: could it be a replacement for meds? 
LCSW: could be! You can use both…the differentiation I would make is 
meds are quicker. You know you’ll probably see with ADD a change 
over night. Whereas this, you’ve got to come weekly it takes anywhere 
between 300 minutes (so about 10-15 sessions) depending on how 
quickly the client fatigues. Or up to a year. And the great thing with the 
neurofeedback is once you get the brain functioning optimally, you don’t 
need it any more, you’re done. Unless you get a head injury, or a fever 
actually disrupts brain waves, anesthesia, you want to coach people not 
to drink artificial sweeteners… 
Me: so as far as efficacy goes, that’s the real difference between neuro 
feedback and meds is time and expense?  
LCSW: ya…and the duration. The neurofeedback is better because you 
know you’ve got a shot at alleviating it completely 
 
 
This therapy is effective in the treatment of ADD/ADHD and when done to completion 




rarely covered by insurance companies, it can take up to a year to see the full results, 
progress can often be slow, and it takes significant effort and focus from the patient and 
their caregivers. What it does do however, is address some of the root causes of 
disturbances such as trauma and anxiety, which medications cannot do. They cannot 
address the social and individual context in which the patient exists. Nor can they 
ensure long-term efficacy and safety for the child to whom it is being prescribed	(Comer 
et al. 2010). The supremacy of medications as treatment options for children 
experiencing mental illness is complicated by factors of professional roles, cost, time, 
availability, insurance companies, and evidence. These factors need to be examined to 





Chapter 5: Discussion 
 
Biomedicine, Pharmaceuticals, and Mental Health 
 
Health and illness do not exist in isolation. Definitions and decisions regarding 
who is ill and how to treat them are inherently culturally biased and influenced by the 
broader societal context in which they exist (Singer and Baer 1995). For western 
culture, and increasingly for much of the world, biomedicine is a dominant feature of 
this societal context, and its supremacy is twofold. It, like any other dominant ideology 
that gains hegemonic success, is presented as beneficial to society and health at large, 
not just to those who capitalize from its propensity. Once this rhetoric is established, 
biomedicine retains supremacy by avoiding epistemological critiques. Biomedicine is 
exempt from such critical analysis because of its affiliation with “science,” and its 
reputation as a mode of truth-finding through empirical research. Yet using an 
interpretive approach to critical medical anthropology reveals that in fact biomedicine, 
like any other medical system, is esoteric, localized, symbolic, and “doggedly 
relativistic” (Lock and Scheper-Hughes 1996, 43). Once this is realized, biomedicine 
can be analyzed in the same way as any other dominant ideology, as existing within a 
nexus of factors that culminate into certain practices of health and healing. The 




psychotropic medications to children, but other micro and intermediate factors are also 
at play, complicating and often obscuring holistic conversation about mental health. 
Pharmaceuticals are the physical embodiment of biomedicine, addressing 
organic pathology and chemically altering the brain, and their ubiquity in western 
culture has altered how we conceive of illness and care, especially in the field of mental 
health (Van der Geest, Whyte, and Hardon 1996).  Recently however, research has 
begun speaking to power, dismantling the idea that pharmaceuticals are inherently 
appropriate and efficacious treatments, and questioning the placement of mental health 
within the biomedical model. Studies are being published showing that antidepressants 
are one third less effective in treating depression than are simple life changes, such as 
improving sleep patterns (Kirsch 2014), that though the rate of prescriptions have 
increased by 500% since the 1980s, there has been no national reduction in rates of 
nation-wide depression (Hari 2018), and that mental health is acknowledged by the 
WHO as being produced socially (Friedli 2009). We know that “trials are funded by 
pharmaceutical corporations and investment banks, who are motivated more by 
maximizing profit margins than by promoting health” (Hardon and Sanabria 2017, 120). 
And those in positions of power, such as Dr. Dainius Puras, a medical doctor and 
representative of the office of the United Nations High Commissioner for Human 
Rights (UN OHCHR), explain how past research on pharmaceuticals have been 
controlled by invested power structures, and that reductive neurobiological paradigms, 





The biased and selective use of research outcomes has negatively 
influenced mental health policies and services. Important stakeholders, 
including the general public, rights holders using mental health services, 
policymakers, medical students, and medical doctors have been 
misinformed. The use of psychotropic medications as the first line 
treatment for depression and other conditions is, quite simply, 
unsupported by the evidence. The excessive use of medications and other 
biomedical interventions, based on a reductive neurobiological 
paradigm causes more harm than good, undermines the right to health, 
and must be abandoned. (Karter 2017) 
 
Dr. Puras is criticizing the use of reductive, biology-centric paradigms when 
considering mental health interventions, the supremacy of biomedical treatments, and 
the negative influence of biased research used to inform prescribing practices. Several 
interviewees acknowledged these issues of reductionism, biomedical influence, and 
evidence during our conversations: A child psychiatrist said that children were being 
prescribed these medications to make them behave within their social contexts, a 
licensed clinical social worker described how the biomedical model pressured 
prescribers to capitalize on their patients by prescribing medications, a child 
psychologist talked about how disruptive the theory of chemical imbalances has been on 
the promotion of pharmaceuticals as a first line treatment, and several addressed 
concerns over the lack of reliable data. The use of psychotropic medications to treat 
mental illness in children remains in place despite significant research discrediting the 
appropriateness of this model for the specific population at hand (Whittington et al. 




exploration of additional factors within the pharmaceutical nexus, including the micro-
level roles and relationships experienced by professionals (Petryna, Lakoff, and 
Kleinman 2006).  
Biomedicine at the Micro-Level 
  
Interviewees discussed the historical and contemporary role changes between 
different mental health professionals. Though psychiatrists used to be responsible for 
psychotherapeutic care as well prescribing psychotropic medications, over the years 
other professionals (psychologists, social workers, and therapists) began practicing 
therapy while psychiatrists simultaneously moved towards becoming experts in 
prescribing psychotropic medications (Buchanan 2003). The anthropology of expertise 
provides a framework with which to better understand these role changes. It considers 
“the participation of objects, producers, and consumers of knowledge”, recognizing that 
these interactive relationships are “inescapably ideological, implicated in the evolving 
hierarchies of value that legitimate particular ways of knowing as ‘expert’” (Carr 2010, 
17).   
Mental health has undergone several ideological [r]evolutions during the 19th 
and 20th centuries, each one creating and then discarding models with which to 
understand mental health: psychoanalytic theory with its focus on subconscious 
thoughts and memories was replaced by the theory of behaviorism which focused on 
behavior, relationships, and processes, then came humanism and cognitive psychology 
which focused on perception, beliefs, and now the contemporary biomedical school of 




All these models are attempts at better understanding mental health by triangulating 
aspects of the human experience to identify patterns and processes that lead to mental 
health and illness. With the adoption of each new model, different ways of knowing and 
knowledge were validated. What was considered “expertise” changes in tandem with 
these ideological domains, and the same can be seen for biomedicine. Two differences 
with this most recent model however are that it does not include social or psychological 
factors, and it incorporates pharmaceuticals. These medications are socially valued 
objects that define psychiatrists as experts within the biomedical model because they 
cannot be prescribed or even understood without expert assistance and interpretation 
(Carr 2010). Psychiatrists, by nature of their medical training, have affiliated themselves 
with psychotropic medications and have the capability of interpreting them for other 
medical professionals, mental health professionals, and patients. This professional 
reliance on psychiatrists to prescribe and interpret psychotropic medications has cleaved 
a distinct role for psychiatry within mental health as well as established them as experts 
within the biomedical model. A current change in the supply and demand of care 
however has caused psychiatrists to share their expert knowledge outside of the field.  
Mental health professionals are witnessing a national crisis amongst children. 
Due to the extended schooling and accompanying debt described in this project, 
psychiatrists are in limited supply, especially those who specialize in children (Williams 
2015). Concurrently, there is an unprecedented rise in children and families seeking 
mental health services (Williams 2015). This inability of child psychiatrists to meet the 




interviewees. This deficit has created practice and policy changes that promote an 
increase in the availability of prescription treatments by utilizing non-psychiatric 
physicians. Tele-health, emergency room consultations, and educational programs were 
all described by interviewees as resources for primary care physicians and pediatricians 
to consult with psychiatrists regarding psychotropic medication prescriptions. Because 
of the lack of child psychiatrists, families are turning to these other physician-types to 
receive prescription drug treatments for their children (Smith 2012). A child psychiatrist 
I spoke with described this process as an effort to “triage” the growing need for 
pediatric interventions and these collaborative resources connect physicians with 
psychiatric guidance on medication side effects, dosage levels, indications, and 
interactions. This collaboration means that psychiatrists are disseminating the 
knowledge that was used to define them as biomedical experts in the mental health field 
with other prescribers. Psychiatrists are openly and willingly providing other prescribers 
with council regarding the prescription of these medications, serving to both solidify 
their standing within the biomedical profession and creating additional resources for 
children to receive psychotropic prescriptions.  
While this collaboration is certainly providing more resources to help children 
access psychotropic medications, it does not address the increasing prevalence of 
pediatric mental illness. Through my interviews it appears that though other types of 
mental health professionals are available, can be more cost effective, and can provide 




most often utilized to simply monitor psychiatric patients once they appear to be 
“stable” on their new medications. This disconnect between need and utilization may be  
understood as an ideological shift between professionals, where those operating within 
the biomedical model are being reinforced only to pursue and utilize other biomedical 
professionals and treatments. 
 
Resources and Access 
 
Interview topics regarding resources and access were primarily focused on 
psychiatrists and medications. Though other care providers and treatments are available, 
many interviewees still identified access as a prominent barrier between children and 
care.  Access, in this context, must therefore be understood as access to prescribers and 
prescriptions, and not access to care in general. The access model created by Drs. 
Levesque, Harris and Russel (2013) conceptualizes the importance and impact access 
has on health and health outcomes. This model represents both supply side (provider) 
and demand side (patient) access factors. For this thesis the components of access being 
analyzed are availability such as workforce shortages, extended wait times, and 
alternative treatment options, affordability such as what is covered for patients and how 
professionals are reimbursed, and acceptability or the research and evidence used to 
inform prescribing practices. 
The lack of available psychiatrists who specialize in children and adolescents 
does not match the enormous and growing number of children in need of care. As of 




with an approximate 15 million children requiring services (Williams 2015). This low 
proportion of professionals with the ability to prescribe has created long wait times for 
patients. The average wait time in the U.S. for an initial appointment with a child 
psychiatrist in a major city is 50 days (Steinman et. al 2015). These statistics, and the 
responses of interviewees in this project seem to agree that there are not enough 
prescribers to attend to the needs of mentally ill children. Yet it is important to parse out 
here that it is not a deficit of mental health professionals being discussed, but a deficit 
of psychiatrists. This commentary reflects the hegemonic ideology that prescribers and 
medications are the most appropriate treatment route for pediatric mental illnesses. 
However, as can be seen through comments made by several interviewees, the ubiquity 
of these medications among children is not a result of their efficacy, but a result of 
ideological, cultural, institutional, financial, and political factors. 
Once a psychiatrist becomes available, the next hurdle for access to care is 
affordability. Professionals are reimbursed for their services through third party payers, 
namely insurance companies, for whom they code their services, indicating how much 
they will be reimbursed (Bachman et al. 2006). As both an adult and child psychiatrist 
told me, psychiatrists receive the highest reimbursement rates for their services, higher 
than psychologists, counselors, therapists, and social workers. Of all these groups, and 
all the available services, the highest reimbursement possible comes from the 
prescribing of a psychotropic medication. This financial incentive was identified by 
several interviewees as a factor in the prescribing of these medications.  In addition, for 




companies such as Medicaid are not sufficient, and they do not accept that form of 
coverage. This leaves a limited number of professionals considered “with-in” network, 
with the majority of care providers falling “out-side” of network, meaning patients are 
required to pay for services out of pocket. These cost constraints from both the supply 
and demand side of care are having an impact on the type of treatment pediatric mental 
health patients are receiving.  
According to several interviewees, another barrier exists between children and 
mental health care: appropriateness. Appropriateness of care is dictated by the amount 
of research and evidence available to professionals to inform their practices as well as 
what medications are approved of by the FDA (Levesque, Harris, and Russell 2013). 
There are obvious risk factors when conducting research with children and according to 
my interviewees, pharmaceutical companies have historically shied away from this 
population. This has led to a limited amount of research regarding these medications in 
pediatric populations, with the research that is available often reflecting short term and 
questionable results (Whitaker and Cosgrove 2015). This lack of research has hindered 
the ability of the FDA to approve psychotropic medications for children, forcing 
practitioners to prescribe off-label medications when treating children, meaning that 
they are prescribing without FDA guidelines regarding safety, efficacy, or 
appropriateness (Brenner 2014; Comer et al. 2010).  Though a child psychiatrist told me 
that off-label prescribing is common across pediatrics in general, it is an important 
element to consider in prescribing psychotropic medications because so little is known 




and FDA approval coupled with increases in prescription rates for children begs the 
question as to how exactly these practices are “evidence-based”?  
 
The Nexus of Influence 
 
The biomedical system within the United States exists within a political, social, 
and economic context (Petryna, Lakoff, and Kleinman 2006). The structure and 
organization of these powerful institutions (state bureaucracies, welfare programs, 
insurance companies, research institutions, etc.) directly impact health policies and the 
way illness is conceptualized and treated (Petryna, Lakoff, and Kleinman 2006). While 
these power structures are prominent and broad in reach, how exactly they influence 
prescribing practices is often unclear. The nexus that mental health exists within helps 
reveal the interactions and interconnectedness of these power structures as they relate to 
health and prescription medications (Petryna, Lakoff, and Kleinman 2006).  
 The pharmaceutical industry is a key player within this nexus of influence, as it 
creates and promotes psychotropic medications. Sadly, health is often not the primary 
motivator of this industry and instead it focuses its attention on markets that are 
economically stable and have a reliable consumer base. The global sale of 
antidepressants grew 5% in 2002, and the sale of antipsychotics by 19% (ranking them 
as the 4th and 5th leading class of global pharmaceutics respectively), reinforcing the 




(Petryna, Lakoff, and Kleinman 2006). The success of these drug sales reflects the 
reliable market the industry has tapped into and secured through the introduction of 
direct to consumer advertising. 
In 1997, North American pharmaceutical companies were granted permission by 
the U.S. FDA to run prescription drugs advertisements on television (Payton and Thoits 
2011). Drug companies, through direct to consumer advertising (DTCA), have 
influenced the conversation surrounding mental health nomenclature and drug 
treatments in a profound way. By 2002 (5 years after DTCA was initiated) over 81% of 
respondents in an FDA survey had been exposed to DTCAs targeting mental health 
(Payton and Thoits 2011). The average viewer had seen “100 minutes of pharmaceutical 
commercials for every minute spent with his or her doctor, or more than 30 hours of 
television advertisements per year” and found that consumers with higher exposure to 
DTCAs were more likely to request advertised drugs (Payton and Thoits 2011). The 
pharmaceutical industry and their ability to advertise directly to consumers solidified 
their stability in the western market by controlling the narrative surrounding mental 
health and its treatments. A concern mentioned by several interviewees surrounding one 
of these narratives as it relates to pharmaceuticals is causality.  
According to a licensed clinical social worker and a child psychiatrist, we are 
not focusing on causality. We do not know why these children are experiencing mental 
health issues, or what is causing unwanted symptoms, and we have neither the time, 
money, nor resources to do anything about it other than treat their symptoms with 




aspects of mental illness, but not psychological or social factors. This is a reductionist 
way of treating mental illness, and one that has been seen in mental health care before. 
During the 1950s and 60s, many women were diagnosed with “nerves” (Hari 2018). 
After 1949 it was commonly believed in the United States that there could be no greater 
fulfilment for a woman than being a successful housewife. Yet as this post WW-II 
sentiment took hold across the country, women who were achieving this coveted 
position of middle-class housewifery were simultaneously reporting an increase in 
depression and anxiety (Friedan 1984). While it was thought that marriage, relative 
material comfort, financial stability, social status, and motherhood would satisfy any 
woman, many felt isolated, trapped, undereducated, and a lack of identity. 
Advertisements bombarded women with desirable household appliances and beauty 
campaigns that reinforced the idea that women should be naturally satisfied by domestic 
bliss. Betty Friedan called this phenomenon “the problem that has no name”, because 
the possibility that the negative psychological symptoms experienced by many women 
were the direct result of their domestic roles was not discussed in the public domain 
(Friedan 1984). Instead it was often treated by Miltown, a drug coined as a “women’s 
drug” prescribed to assuage their many “vague complaints and anxieties”. (Prewitt 
2015). The epidemic of unexplainable “nerves” that swept middle class female America 
did in fact have a catalyst, but dominant social commentary disabled any productive 
conversation. Women were instead viewed as being mentally weak and in need of 
medical intervention for their seemingly self-induced psychological discomforts. It is 




health issues are being trapped in a world view handed to them by parents, doctors, and 
industries. Their emotional and behavioral disturbances reflect psychological, social and 
biological factors, which necessitates a broader and more inclusive conversation of 
pathology and treatment.   
These interviews show that the conversation surrounding children and 
psychotropic medications is obstructed because of its placement within the biomedical 
model which itself exists within a political and economic context. The biomedical 
model is seen by both the public and professionals as an objective, scientific way to 
measure and treat health/illness, and has thus far been exempt from being critically 
analyzed like any other esoteric system of care (Lock and Scheper-Hughes 1996). As is 
seen in these interviews however, prescribing decisions are not always based on 
empirical, evidence-based, discrete diagnoses of illness. The prescription of these 
medications to children are often influenced by professional role changes, a lack of care 
providers, financial barriers, issues of evidence and approved medications, advertising, 
and the pharmaceutical industry. These factors show that biomedicine and 
pharmaceuticals are not the direct result of fact and truth, but of influence, decisions, 
negotiations, and meanings (Lock and Scheper-Hughes 1996).  
By recognizing biomedicine as a relativist system, it is even more striking that 
psychological and social factors have been excluded as viable causal explanations for 
mental illness. The exclusion of these factors reinforces the idea that biomedicine is 
purely scientific and void of culture and continues to reduce and disable holistic 




experiences of pediatric patients and their families all create the context in which 
mental health, pharmaceuticals, and professionals exist. The professionals interviewed 
for this thesis all practice within their own unique version of this context. Their 
practices are all, to varying degrees, influenced by professional roles, access, cost, 
evidence, and the biomedical model. Their experiences, recorded in this thesis, reflect 
their individual negotiations and choices made within these contexts and help reveal 
how each of these professionals views themselves, their practice, and the role of 




Chapter 6: Conclusion 
 
Mental illnesses are generally thought to be caused by one or more of the 
following: biological, psychological, and social factors (Wilson 1993). Yet since the 
1980s, psychological and social explanations and treatments for mental illness have 
been consistently ignored as primary, viable, and competitive treatment options to 
pharmaceuticals (Wilson 1993). A national cultural shift towards medicalization has 
moved mental health into the biomedical model, a move that was supported and 
propelled by insurance companies, pharmaceutical companies, national professional 
organizations, and the public (Wilson 1993), This shift has had several positive 
outcomes. It has helped re-categorize issues such as PTSD as valid and recognized 
disorders, reducing stigma and increasing the availability of support and treatment. It 
has led to the removal of homosexuality from the DSM as there are no biological 
markers to indicate it as a symptom of neurological or behavioral deviance. And it has 
helped emphasize the need for empirical data collection methods to increase the 
consistency of diagnoses between patients and among professionals. It has brought 
prestige back to psychiatry through its new affiliation with “science” and “medicine”. 
And it has provided a physical, tangible option for hope in the form of psychotropic 




minimized. However, the biomedical model also constrains and limits the way mental 
health is now conceived of and experienced within its larger economic, political, and 
social contexts.  
Often, symptoms of mental illness such as depression or anxiety are signals that a 
psychological or social need is not being met, just as hunger and fatigue are signals that 
people need to eat and sleep. It is adaptive. Yet instead of addressing external factors of 
causality, biomedicine emphasizes the management of symptoms through the use of 
pharmaceutical drugs. The structural changes that took place within mental health over 
the past forty years have reframed the conversation into a purely pharmacological one 
and are now impacting the treatment of children with mental health issues regardless of 
the overwhelming evidence and research that advises against the ubiquitous use of 
psychotropic medications. The literature reviewed for this thesis, as well as some of my 
interviewees, describe these medications as appropriate only as a “last resort”. But in 
their description of practice, due to constraining circumstances, other interviewees 
describe them as their only resort. The data collected in this thesis show that for these 
professionals, the use of psychotropic medications for children with mental health issues 
is often the result of financial, political, institutional and biomedical pressures and not of 
objective scientific evidence or diagnoses.  
 Prescribers are not, of course, malevolent players simply operating under the 
control of industry puppeteers. They are caregivers, working under difficult and 
constraining circumstances, navigating a complex and sometimes invisible nexus of 




the conversation, reducing mental illness in children to a biological experience. Though 
these medications are sometimes effective in reducing unwanted symptoms, they do not 
address underlying pathology, which may be caused by a combination of biological, 
psychological, and social factors. It is imperative that we examine where these factors 
can be reinserted into the conversation of how to care for and treat children with mental 
illness. There must be a balance struck between benefiting from biomedicine when 
appropriate, while retaining a critical gaze at dominant ideologies, and reframing 
conversations of health back towards the patients and their individual experience of 
health and illness.  
 Anthropologists can continue this conversation by looking at other areas of health 
where discourse has been limited and reduced exclusively to biology. Exploring where, 
when, and how other factors of health lose their voice within the conversation may 
expose a way to prevent their elimination from happening in the future. It is also 
important to record the consequences of this silencing, emphasizing that a holistic 
approach to care will always be more appropriate than a reductionist one.  
 The job of mental professionals is much harder. Reintroducing psychological and 
social factors and treatments as competitive and complementary forms of care in the face 
of biomedicine and pharmaceuticals is daunting. Many interviewees said that the best 
form of treatment for children with mental illness was a combination of therapy and 
medications, but the efficacy of either one cannot be known if being used in tandem with 
the other. Perhaps, as the pharmaceutical board member discussed regarding the 




professionals can be encouraged and reminded that they have the ability to recommend a 
medication be decreased or discontinued. They can advocate for their patients and 
collaborate with psychiatrists to decrease the use of medications and increase the use of 
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